The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $119.54

Today's change+2.72 +2.33%
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $119.54

Today's change+2.72 +2.33%
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.

Alexion Pharmaceuticals Inc crosses above 20-day moving average

Alexion Pharmaceuticals Inc closed up sharply Monday, rallying (U.S.)$2.72 or 2.33% to (U.S.)$119.54 and crossing above its 20-day moving average. Over the last five days, shares have gained 0.60%, but are currently unchanged over the last year to date. Shares have underperformed the S&P 500 by 38.37% during the last year.

Key company metrics

  • Open(U.S.) $117.99
  • Previous close(U.S.) $116.82
  • High(U.S.) $120.42
  • Low(U.S.) $117.51
  • Bid / Ask(U.S.) $110.50 / (U.S.) $151.00
  • YTD % change-2.30%
  • Volume2,812,887
  • Average volume (10-day)1,699,376
  • Average volume (1-month)1,763,310
  • Average volume (3-month)2,448,934
  • 52-week range(U.S.) $109.12 to (U.S.) $159.93
  • Beta1.34
  • Trailing P/E67.93×
  • P/E 1 year forward22.31×
  • Forward PEG1.18×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.76
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.63%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue831799753701
Total other revenue--------
Total revenue831799753701
Gross profit763728692642
Total cost of revenue67716159
Total operating expense704620558535
Selling / general / administrative260230232233
Research & development206196179167
Depreciation / amortization80828089
Interest expense (income), net operating--------
Unusual expense (income)91417-13
Other operating expenses, total--------
Operating income127179195166
Interest income (expense), net non-operating-25-----24
Gain (loss) on sale of assets--------
Other--------
Income before tax104158170144
Income after tax929411592
Income tax, total12645551
Net income929411592
Total adjustments to net income--------
Net income before extra. items929411592
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items929411592
Inc. avail. to common incl. extra. items929411592
Diluted net income929411592
Dilution adjustment--------
Diluted weighted average shares228226226227
Diluted EPS excluding extraordinary itemsvalue per share0.400.420.510.41
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.760.530.530.37